Theresa Vicroy, MD
Internal Medicine · Houston, TXNPI 1205876232
Payments from drug & device makers
Across 376 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Novo Nordisk$549
- Pfizer$537
- Lilly USA, LLC$339
- GSK$304
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,02199%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 80 | $1,401 |
| AstraZeneca | 73 | $1,199 |
| Novo Nordisk | 23 | $549 |
| Pfizer | 26 | $537 |
| Lilly USA, LLC | 16 | $339 |
| GSK | 16 | $304 |
| Exact Sciences | 13 | $270 |
| Boehringer Ingelheim | 13 | $263 |
| AbbVie(2 entities) | 15 | $225 |
| Johnson & Johnson | 13 | $215 |
| Astellas Pharma US Inc | 11 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $172 |
| Alphatec Spine, Inc | 1 | $141 |
| Merck | 8 | $135 |
| Bayer | 6 | $126 |
| Novartis | 6 | $115 |
| Radius Health, Inc. | 5 | $111 |
| Esperion Therapeutics, Inc. | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Mylan Specialty L.p. | 4 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $71 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Genentech USA, Inc. | 3 | $58 |
| Vivus LLC | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Corium, LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Eisai Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Biogen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Porous Ti Cervical$141
- KODIAK$141
- EVENITY$122
- Ozempic$122
How this compares
$7,058 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $216,203 |
| EliquisApixaban | 61 | $76,776 |
| XareltoRivaroxaban | 68 | $61,501 |
| TrulicityDulaglutide | 62 | $60,243 |
| MounjaroTirzepatide | 57 | $58,544 |
| ProliaDenosumab | 23 | $39,310 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $37,016 |
| MyrbetriqMirabegron | 41 | $35,844 |
| Repatha SureclickEvolocumab | 46 | $35,329 |
| FarxigaDapagliflozin Propanediol | 37 | $30,803 |
| JardianceEmpagliflozin | 19 | $29,330 |
| Bydureon BciseExenatide Microspheres | 12 | $28,103 |
| NexletolBempedoic Acid | 28 | $26,421 |
| JanuviaSitagliptin Phosphate | 16 | $20,660 |
| TradjentaLinagliptin | 12 | $14,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $549 | $216,203144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $339 | $118,786119 claims |
| PfizerEliquis, Premarin, Paxlovid | $537 | $84,956122 claims |
| Johnson & JohnsonXarelto | $215 | $61,50168 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $304 | $45,59851 claims |
| Boehringer IngelheimJardiance, Tradjenta | $263 | $43,88731 claims |
| AmgenProlia | $1,401 | $39,31023 claims |
| Astellas Pharma US IncMyrbetriq | $206 | $35,84441 claims |
| AstraZenecaFarxiga | $1,199 | $30,80337 claims |
| Esperion Therapeutics, Inc.Nexletol | $104 | $26,42128 claims |
| AbbVieLinzess, Synthroid | $225 | $23,325123 claims |
| MerckJanuvia | $135 | $20,66016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.